Silence Therapeutics PLC

XRP2

Company Profile

  • Business description

    Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

  • Contact

    72 Hammersmith Road
    LondonW14 8TH
    GBR

    T: +44 2034576900

    E: [email protected]

    https://www.silence-therapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    116

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,462.6040.900.49%
CAC 407,747.0952.650.68%
DAX 4023,501.21148.520.64%
Dow JONES (US)41,308.5859.87-0.14%
FTSE 1008,554.8323.220.27%
HKSE22,867.7491.820.40%
NASDAQ17,962.7034.560.19%
Nikkei 22537,503.33574.701.56%
NZX 50 Index12,605.07138.041.11%
S&P 5005,668.414.470.08%
S&P/ASX 2008,231.2039.500.48%
SSE Composite Index3,342.0010.00-0.30%

Market Movers